Introduction

Dr. Helen Hestlop discusses banked allogeneic immune effector cells with blood author Dr. Jeffrey Miller. Autologous CAR T-cell therapies for lymphoma and myeloma have had very impressive activity in patients with relapse disease. There are two other topics that I think Jeff Miller is going to cover: benefits of using IPSCs as a source of immune effectors and the other would be using natural killer cells. All these articles are integrated.